Showing 1771-1780 of 5771 results for "".
- Aldeyra Therapeutics Announces Positive Topline Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap for Dry Eye Diseasehttps://modernod.com/news/aldeyra-therapeutics-announces-positive-topline-data-from-phase-2-dry-eye-chamber-clinical-trial-of-reproxalap-for-dry-eye-disease/2480557/Aldeyra Therapeutics announced positive topline data from a phase 2 clinical trial comparing ocular discomfort and itching symptom scores of reproxalap ophthalmic solution 0.25%, an investigational new drug, versus Xiidra (lifitegrast ophthalmic solution 5%) in patients with dry ey
- Regenxbio Announces Initiation of Second Pivotal Trial in RGX-314 Clinical Program for the Treatment of Wet AMD Using Subretinal Deliveryhttps://modernod.com/news/regenxbio-announces-initiation-of-second-pivotal-trial-in-rgx-314-clinical-program-for-the-treatment-of-wet-amd-using-subretinal-delivery/2480556/Regenxbio announced the initiation of ASCENT, the second of two phase 3 pivotal trials to evaluate the efficacy and safety of subretinal delivery of RGX-314 in patients with wet age-related macular degeneration (AMD). ASCENT, the first trial to be initiated by Regenxbio under the e
- EyePoint Pharmaceuticals Announces 2022 Clinical Plans and Highlights Recent Corporate and Clinical Achievementshttps://modernod.com/news/eyepoint-pharmaceuticals-announces-2022-clinical-plans-and-highlights-recent-corporate-and-clinical-achievements/2480554/EyePoint Pharmaceuticals announced its 2022 clinical pipeline plans and highlighted recent corporate achievements driven by its lead pipeline candidate, EYP-1901, a potential 6-month intravitreal treatment targeting wet age-related macular degeneration (AMD).
- Glaukos Announces FDA 510(k) Clearance of iPRIME Viscodelivery Systemhttps://modernod.com/news/glaukos-announces-fda-510k-clearance-of-iprime-viscodelivery-system/2480553/Glaukos announced that it has received 510(k) clearance from the FDA for the iPRIME Viscodelivery System, a sterile, single-use, minimally-invasive device for the delivery of viscoelastic fluid during ophthalmic surgery. “Since the introduction of our first&nb
- Gentex Announces Partnership With eSight To Develop Next Generation Digital Eyewearhttps://modernod.com/news/gentex-announces-partnership-with-esight-to-develop-next-generation-digital-eyewear/2480538/Gentex announced that it is partnering with eSight, provider of vision enhancement technology, to develop and manufacture the next generation of mobile electronic eyewear designed to help people living with visual impairments. Terms of the d
- Glaukos Announces Retirement of William J. Link, PhD, as Chairman of the Board; and Election of Thomas W. Burns as New Chairmanhttps://modernod.com/news/glaukos-announces-retirement-of-william-j-link-phd-as-chairman-of-the-board-and-election-of-thomas-w-burns-as-new-chairman/2480530/Glaukos announced that William J. Link, PhD, will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos’ Board and has served as Chairman since June 2001. In connection with Dr. Link’s retirement, the Board has appointed Thomas W. Burns, Glaukos&rs
- Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX for the Treatment of Wet AMDhttps://modernod.com/news/clearside-biomedical-announces-positive-safety-results-from-oasis-phase-12a-clinical-trial-of-cls-ax-for-the-treatment-of-wet-amd/2480529/Clearside Biomedical announced positive safety results from OASIS, its ongoing phase 1/2a clinical trial of CLS-AX (axitinib injectable suspension) administered by suprachoroidal injection via Clearside’s SCS Microinjector. OASIS is evaluating CLS-AX for the treatment o
- Nicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucomahttps://modernod.com/news/nicox-announces-first-patient-in-china-screened-in-the-ongoing-ncx-470-denali-phase-3-trial-in-glaucoma/2480521/Nicox SA announced that the first patient has been screened in China in the ongoing Denali phase 3 clinical trial, opening the way for new drug application (NDA) submissions in both the United States and China for NCX 470, Nicox’s lead clinical product candidate in glaucoma. Denali, wh
- Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucomahttps://modernod.com/news/ivantis-announces-first-patient-enrolled-in-pivotal-clinical-trial-evaluating-the-hydrus-microstent-in-standalone-migs-for-mild-to-moderate-glaucoma/2480515/Ivantis announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent cataract surgery. Up to 80% of glaucoma patients have mild to moderate disease severity, and a sta
- TearLab Announces Adam Szaronos as President and CEO, and Jim Mazzo as Executive Chairman of the Boardhttps://modernod.com/news/tearlab-announces-adam-szaronos-as-president-and-ceo-and-jim-mazzo-as-executive-chairman-of-the-board/2480506/TearLab announced that Adam Szaronos has been appointed President and Chief Executive Officer by the company's Board of Dir